A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this phase I study is to evaluate the safety and efficacy of pembrolizumab in combination with Lenvatinib in patients with pancreatic ductal adenocarcinoma.
General Information
NCT#: NCT05273554
Study ID: 2021-0274
Trial Phase: Phase I
Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: Pembrolizumab, Lenvatinib